Liang Kong
Chief Tech/Sci/R&D Officer presso ALPHAMAB ONCOLOGY
Profilo
Liang Kong currently works at Jiangsu Alphamab Biopharmaceuticals Co., Ltd, as Vice President and Alphamab Oncology, as Vice President-Clinical Operations from 2018.
Mr. Kong also formerly worked at FibroGen (China) Medical Technology Development Co. Ltd., as Director-Clinical Operations from 2013 to 2017, Roche (China) Co. Ltd., as Manager-Global Study from 2012 to 2013, and Hua Medicine (Shanghai) Co., Ltd., as Vice President-Clinical Operations from 2017 to 2018.
Mr. Kong received his graduate degree in 2004 from China Pharmaceutical University.
Posizioni attive di Liang Kong
Società | Posizione | Inizio |
---|---|---|
ALPHAMAB ONCOLOGY | Chief Tech/Sci/R&D Officer | 01/06/2018 |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Jiangsu Alphamab Biopharmaceuticals Co., Ltd Pharmaceuticals: MajorHealth Technology Part of Suzhou Alphamab Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd is a private company that manufactures and distributes therapeutics for cancer treatment. Jiangsu Alphamab Biopharmaceuticals Co., Ltd is based in Suzhou, China. The Chinese company was founded in 2015 by Ting Xu. Ting Xu has been the CEO since 2015. | Corporate Officer/Principal | - |
Precedenti posizioni note di Liang Kong
Società | Posizione | Fine |
---|---|---|
Hua Medicine (Shanghai) Co., Ltd.
Hua Medicine (Shanghai) Co., Ltd. BiotechnologyHealth Technology Hua Medicine (Shanghai) Co., Ltd. is a Chinese biotechnology company that focuses on the clinical needs of diabetic patients. The private company is based in Shanghai, China. The company has brought together high-end talents and scientific and technological resources to develop the world's first dorzagliatin (hms5552) for the treatment of type 2 diabetes. Hua Medicine has conducted two phase III clinical trials in 2019, targeting type 2 diabetes patients who have failed to treat the disease with other medications. The company plans to expand the advanced concepts of personalized therapy and management of diabetes to achieve effective control of diabetes and metabolic diseases and complications. The company was founded in 2011 by Li Chen, who has been the CEO since then. | Corporate Officer/Principal | 01/05/2018 |
FibroGen (China) Medical Technology Development Co. Ltd.
FibroGen (China) Medical Technology Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., FibroGen (China) Medical Technology Development Co., Ltd. is a biomedical technology company based in Beijing, China. FibroGen () is dedicated to developing new mechanisms of action or "best-in-class" innovative drugs and medical devices to meet the unmet clinical needs of Chinese patients. The Chinese company also provides a platform to report adverse events related to FibroGen roxadustat products. The private company was founded in 2011. Christine Chung L. has been the CEO of the company since 2019. | Corporate Officer/Principal | 01/09/2017 |
Roche (China) Co. Ltd. | Corporate Officer/Principal | 01/01/2013 |
Formazione di Liang Kong
China Pharmaceutical University | Graduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
ALPHAMAB ONCOLOGY | Health Technology |
Aziende private | 4 |
---|---|
Roche (China) Co. Ltd. | |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Jiangsu Alphamab Biopharmaceuticals Co., Ltd Pharmaceuticals: MajorHealth Technology Part of Suzhou Alphamab Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd is a private company that manufactures and distributes therapeutics for cancer treatment. Jiangsu Alphamab Biopharmaceuticals Co., Ltd is based in Suzhou, China. The Chinese company was founded in 2015 by Ting Xu. Ting Xu has been the CEO since 2015. | Health Technology |
Hua Medicine (Shanghai) Co., Ltd.
Hua Medicine (Shanghai) Co., Ltd. BiotechnologyHealth Technology Hua Medicine (Shanghai) Co., Ltd. is a Chinese biotechnology company that focuses on the clinical needs of diabetic patients. The private company is based in Shanghai, China. The company has brought together high-end talents and scientific and technological resources to develop the world's first dorzagliatin (hms5552) for the treatment of type 2 diabetes. Hua Medicine has conducted two phase III clinical trials in 2019, targeting type 2 diabetes patients who have failed to treat the disease with other medications. The company plans to expand the advanced concepts of personalized therapy and management of diabetes to achieve effective control of diabetes and metabolic diseases and complications. The company was founded in 2011 by Li Chen, who has been the CEO since then. | Health Technology |
FibroGen (China) Medical Technology Development Co. Ltd.
FibroGen (China) Medical Technology Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., FibroGen (China) Medical Technology Development Co., Ltd. is a biomedical technology company based in Beijing, China. FibroGen () is dedicated to developing new mechanisms of action or "best-in-class" innovative drugs and medical devices to meet the unmet clinical needs of Chinese patients. The Chinese company also provides a platform to report adverse events related to FibroGen roxadustat products. The private company was founded in 2011. Christine Chung L. has been the CEO of the company since 2019. | Health Technology |
- Borsa valori
- Insiders
- Liang Kong